How will state exchanges handle cancer drugs?
More like this
- A Conversation With F. Randy Vogenberg, PhD, RPh: Changing Market for Pharmacy Benefits
- Do the Numbers Add Up for Oral Oncology Quantity-Limit Programs?
- Rebates for Anti-Anemia Drugs Draw Response From FDA, CMS
- Free Statins Disrupt Pharmacy Benefit Plans
- Health Care Reform Injects Economics Into the Biologics 'Value Equation'
|Customer Analytics & Engagement in Health Insurance||Chicago||December 4–5, 2014|
|Pharmaceutical and Biotech Clinical Quality Assurance Conference||Alexandria, VA||December 4–5, 2014|
|6th Semi-Annual Diagnostic Coverage and Reimbursement Conference||Boston||December 4–5, 2014|
|9th Semi-Annual Medical Device Coverage and Reimbursement Conference||San Diego||December 5, 2014|
|8th Annual Medical Device Clinical Trials Conference||Chicago||December 8–9, 2014|
|HealthIMPACT Southeast||Tampa, FL||January 23, 2015|